0000950170-24-046984.txt : 20240423
0000950170-24-046984.hdr.sgml : 20240423
20240423163909
ACCESSION NUMBER: 0000950170-24-046984
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240419
FILED AS OF DATE: 20240423
DATE AS OF CHANGE: 20240423
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wan Jerry
CENTRAL INDEX KEY: 0001828041
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 033-80623
FILM NUMBER: 24865352
MAIL ADDRESS:
STREET 1: 1040 WEST GEORGIA STREET
STREET 2: SUITE 1030
CITY: VANCOUVER
STATE: A1
ZIP: V6E 4H1
FORMER NAME:
FORMER CONFORMED NAME: Wann Jerry
DATE OF NAME CHANGE: 20201013
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACHIEVE LIFE SCIENCES, INC.
CENTRAL INDEX KEY: 0000949858
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 954343413
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22722 29TH DR. SE
STREET 2: SUITE 100
CITY: SEATTLE
STATE: WA
ZIP: 98021
BUSINESS PHONE: 425-686-1500
MAIL ADDRESS:
STREET 1: 22722 29TH DR. SE
STREET 2: SUITE 100
CITY: SEATTLE
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20080821
FORMER COMPANY:
FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19950825
4
1
ownership.xml
4
X0508
4
2024-04-19
0000949858
ACHIEVE LIFE SCIENCES, INC.
ACHV
0001828041
Wan Jerry
1040 WEST GEORGIA STREET
SUITE 1030
VANCOUVER
A1
V6E 4H1
BRITISH COLUMBIA, CANADA
false
true
false
false
Principal Accounting Officer
false
Common Stock
2024-04-19
4
M
false
5625
0
A
12057
D
Common Stock
2024-04-19
4
F
false
2250
4.51
D
9807
D
Performance Restricted Stock Unit (PRSU)
2024-04-19
4
M
false
5625
0
D
2026-01-03
Common Stock
5625
0
D
Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of PRSUs.
Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone.
Sandra Thomson as attorney-in-fact for Jerry Wan
2024-04-23